ANGLE's Parsortix System Aids Important Findings Presented in Five Posters at AACR Annual Meeting April 16-20

ANGLE plc announces that its Parsortix cell separation system will be featured in five different poster presentations at the American Association for Cancer Research Annual Meeting to be held April 16-20 in New Orleans. The presentations, from researchers around the world, highlight the ability of Parsortix to effectively capture viable circulating tumour cells (CTCs) for downstream analysis to aid in the investigation of pancreatic, stage IV breast, bladder and lung cancers. One poster of note reported genomic differences between CTCs that have been isolated using the Parsortix size and deformability-based method and those that have been isolated using existing technology based on EpCAM affinity.

This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20160413005408/en/

ANGLE Parsortix cell separation system (Photo: Business Wire)

Presentation of the posters will occur at the following times:

Mon, Apr 18, 8:00 AM - 12:00 PM
Molecular profiling of circulating tumor cells as a surrogate for distant metastasis in stage IV breast cancer
Mon, Apr 18, 8:00 AM - 12:00 PM
Silencing of ERK2 reverses EMT and suppresses the CSC phenotype inhibiting lung metastasis in triple­negative breast cancer
Mon, Apr 18, 1:00 - 5:00 PM
Digital sorting and single-cell genomic profile comparison of lung adenocarcinoma CTCs between EpCAM and size-based enrichment methods
Tue, Apr 19, 8:00 AM - 12:00 PM
Circulating tumor cell enrichment and dielectric manipulation for ultra-pure cell recovery in advanced bladder cancer
Tue, Apr 19, 1:00 - 5:00 PM
Combined circulating tumour cell (CTC) and circulating tumor DNA (ctDNA) analysis of blood from patients with pancreatic cancer

"The breadth of research represented in five presentations are testimony to the ability of the Parsortix system to serve as a valuable cell separation tool for researchers seeking to understand the mechanisms of various forms of cancer,” said Andrew Newland, CEO of ANGLE, plc. "We are excited that researchers across the globe continue to find our cell separation technology a useful tool to continue advancing the field of liquid biopsies.”

About ANGLE plc

ANGLE is a UK-based specialist medtech company commercializing the Parsortix^TM system, a cell separation technology that enables a simple blood test to harvest targeted cells, such as circulating tumor cells (CTCs) for molecular profiling and analysis. Parsortix^TM can help deliver targeted cancer diagnostics designed to inform personalized treatment of cancer. It is also designed to be compatible with existing major medtech analytical platforms and enable companion diagnostics for major pharma in helping to identify patients that will benefit from a particular drug and then monitoring the drug’s effectiveness. ANGLE has established formal collaborations with world-class cancer centers and is working with these cancer centers to demonstrate key applications for its Parsortix^TM non-invasive cancer diagnostic system as a liquid biopsy. In addition to cancer cells, the Parsortix^TM technology has the potential for deployment for other clinically significant cell types in the future.

ANGLE’s Parsortix^TM system is available for research use worldwide and is CE-IVDD Marked for indicated clinical use in Europe.

ANGLE is a public company trading on the AIM market of the London Stock Exchange under the ticker symbol AGL and in the United States on the OTC-QX market under the ticker symbol ANPCY.

View source version on businesswire.com: http://www.businesswire.com/news/home/20160413005408/en/